Friday, June 19, 2020 12:26:40 AM
In the GS event the question was asked about how do Phase 2 results get duplicated in the critical Phase 3 trials.
Sergio Traversa answers: Good question, can distill it down to two reasons why there is a depression trial fail,
one is the patient selection
and the other is the placebo effect
Why Relmada did well in Phase 2:
First half of test was in clinic, good control of placebo
Relmada uses two diagnostic tools in patient selection:
one is the SAFER test
Link to Safer pdf which helps to reduce the effect of having patients who are not really depressed but may have other CNS disorders.
Placebo effect is actually higher in clinic settings than in outside (at home) settings.
Upon the hiring of Marc de Somer MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety...
he outlined his goals at Relmada...
Recent RLMD News
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 10:55:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:28:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:28:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:11:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:00:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:27:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:27:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:27:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:05:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:01:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 09:18:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 12:53:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:47:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 01:23:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:54:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:29:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:01:43 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM